BruceBMcCallMD

Oncology • South San Francisco, CA

Group Medical Director, Hematology/Oncology

Join to view full profile

Dr. McCall is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McCall's full profile

Already have an account?

Office
1 DNA Way
South San Francisco, CA 94080
Phone+1 415-846-8056

Education & Training

St Mary's Hospital and Medical CenterResidency, Internal Medicine, 2001 - 2004
University of WashingtonResidency, Anesthesiology, 1989 - 1993
University of California San Diego School of MedicineClass of 1989

Publications & Presentations

PubMed

101 citations
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
Asha Nayak-Kapoor, Zhonglin Hao, Ramses F. Sadek, Robin Dobbins, Lisa Marshall
Journal for Immunotherapy of Cancer. 2018-06-20
14 citations
Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors
Colin D. Weekes, Lee S. Rosen, Anna Capasso, Kit Man Wong, Weilan Ye
Cancer Chemotherapy and Pharmacology. 2018-06-15
15 citations
Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cel...
Joachim von Pawel, David R. Spigel, Thomas Ervin, György Losonczy, Fabrice Barlesi
The Oncologist. 2018-06-01

Abstracts/Posters

An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicit...
Bruce McCall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019